NewGen Prices $1.25M Offering at $0.07, NIVF Slides 36%

NewGenIvf Group Limited (NASDAQ: NIVF) priced a reasonable best-efforts public offering expected to raise roughly $1.25 million in gross proceeds, the company announced on 29 September 2026. The deal comprises 17,857,143 Ordinary Shares or Pre-Funded Warrants in lieu thereof at $0.07 per share, with each Pre-Funded Warrant priced at $0.06999 and carrying a $0.00001 exercise price. NIVF traded at $0.3448, down 36.27% on the day, within a $0.3196-$0.4766 range as of 09:42 UTC today.

Context — Why a $1.25 Million Raise Matters for NIVF

NewGen describes itself as a tech-forward, diversified, multi-jurisdictional entity spanning real estate development, digital asset management and reproductive health solutions. The offering is small in absolute dollars but large relative to a share price of $0.3448, because the deal is priced at $0.07 — roughly one-fifth of where the stock last traded. That gap between the offering price and the market price is the mechanism investors are reacting to.

The company said it operates through three named arms: NewGenProperty, focused on real estate development projects in the UAE's Ras Al Khaimah Emirate; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products. Its legacy business includes IVF and assisted reproductive treatment services across Asia.

The report does not disclose the company's prior capital structure, its cash balance before the raise, or how the offering compares with earlier financings. What it does disclose is that a registration statement on Form F-1 (No. 333-298442), filed with the SEC on 20 August 2026, was declared effective on 28 September 2026 — one day before pricing.

That sequencing is the catalyst chain. A shelf declared effective on Monday allowed the company to price a deal on Tuesday, and the market repriced the equity on the same session. The offering is expected to close on or about 30 September 2026, subject to customary closing conditions.

Data — What the Offering Terms Show

The arithmetic is the story. At $0.07 per Ordinary Share across 17,857,143 shares, gross proceeds land at approximately $1.25 million. For each Pre-Funded Warrant sold, the number of Ordinary Shares in the offering decreases on a one-for-one basis, so the headline share count is a ceiling rather than a fixed figure.

Metric	Level
Public offering price per Ordinary Share	$0.07
Pre-Funded Warrant price	$0.06999
Pre-Funded Warrant exercise price	$0.00001
Gross proceeds (expected)	~$1.25 million
NIVF last price	$0.3448
NIVF session move	-36.27%
NIVF session range	$0.3196-$0.4766

The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. The company expects to use net proceeds, together with existing cash, for four stated purposes: investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in the cell-sorting business, and general corporate purposes.

Aegis Capital Corp. is acting as exclusive placement agent. Han Kun Law Offices LLP is U.S. counsel to the company, and Kaufman & Canoles, P.C. is U.S. counsel to Aegis Capital Corp. The report gives no peer comparison and no valuation multiple, so none is asserted here.

Analysis — Where the Dilution Lands

The gap between $0.07 and $0.3448 is the single most informative figure in the release. Buyers in the offering acquire stock at a discount of roughly 80% to the last traded price, which is the conventional structure of a best-efforts placement into a thinly traded small-cap equity. The 36.27% session decline is the market marking that discount to the existing float.

Second-order effects run through the stated use of proceeds. Capital allocated to K25.ai and to Nodexus machine manufacturing and deployment points to the company funding two distinct operating lines from a single small raise. Debt restructuring absorbs a share of proceeds without adding productive assets. For holders, the practical question is whether $1.25 million gross — before placement agent fees and other offering expenses — covers the intended scope of those four buckets.

The counter-argument deserves weight. A best-efforts deal is not a firm-commitment underwriting; the company raises what it sells, and the Pre-Funded Warrant structure gives investors a near-zero-cost conversion path. That structure can broaden participation among buyers who cannot hold warrants at a distance from the strike. It also means the final share count can move in either direction depending on warrant take-up.

Positioning follows mechanically. Existing holders absorbed a 36.27% markdown; offering participants are long at $0.07 with an immediate exercisable warrant. The flow is toward the discounted tranche, and the $0.3196 low of the session range is the level the tape has already tested.

Outlook — What to Watch Next

Three dates anchor the near term. The transaction is expected to close on or about 30 September 2026, subject to customary closing conditions — that is the first checkpoint. A final prospectus describing the terms is to be filed with the SEC, and its contents will confirm the settled share count and the mix of Ordinary Shares versus Pre-Funded Warrants.

Operationally, the deployment of proceeds into K25.ai, debt securities restructuring, and Nodexus machine manufacturing is the second catalyst set. The company gave no timeline for those deployments, so timing remains undisclosed. Third, the Pre-Funded Warrants are exercisable at any time until exercised in full, which makes future share-count disclosures the relevant dilution gauge.

On levels, the report names no support or resistance. The observable reference points are the session range: $0.3196 at the low and $0.4766 at the high, with $0.07 as the offering price. Whether the equity stabilizes above the session low or converges toward the offering price is the condition to track, not a forecast.

Frequently Asked Questions

What does a $0.07 offering price mean for NIVF shareholders?

It sets the price at which new stock enters the float, roughly one-fifth of the $0.3448 last traded level. Existing holders see their proportional claim diluted at that discounted price while the market price adjusts. The one-for-one reduction mechanism means the 17,857,143 share figure falls if Pre-Funded Warrants are sold instead of Ordinary Shares, so the final dilution depends on the mix.

What will NewGen do with the $1.25 million in proceeds?

The company stated four uses: investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in the cell-sorting business, and general corporate purposes. Gross proceeds are approximately $1.25 million before placement agent fees and other offering expenses, so the net amount available for those items is lower than the headline figure.

Who is running the NewGen offering and when does it close?

Aegis Capital Corp. is acting as exclusive placement agent, with Han Kun Law Offices LLP as U.S. counsel to the company and Kaufman & Canoles, P.C. as U.S. counsel to Aegis. The transaction is expected to close on or about 30 September 2026, subject to customary closing conditions. A final prospectus will be filed with the SEC and posted to the regulator's website.

Bottom Line

NewGen priced $1.25 million of stock at $0.07, and NIVF's 36.27% slide is the float repricing to that discount.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.